摘要
波普瑞韦(boceprevir,BOC)和替拉瑞韦(telaprevir,TVR)均为丙型肝炎病毒NS3/4A丝氨酸蛋白酶抑制剂,用于治疗基因1型慢性丙型病毒性肝炎(chronic hepatitis C,CHC)。与现行的CHC的标准治疗方案比较,BOC或TVR联合聚乙二醇干扰素α和利巴韦林的三联疗法可大大提高初治病人的持久病毒应答率,且对既往聚乙二醇干扰素α联合利巴韦林治疗无效的病人也有较好的疗效。BOC和TVR的三联疗法比现行的标准治疗方案有更好的疗效和安全性。可以说,BOC和TVR的临床应用,使基因1型CHC的治疗进入新纪元。
Boceprivir（BOC） and telaprevir（TVR） are all inhibitors targeting hepatitis C virus （HCV） NS3/4A serine pro tease. Both of them are used for the treatment of the patients with genotype 1 chronic hepatitis C （CHC）. A triple therapy scheme, including BOC （or TVR） plus pegylated interferon alpha and ribavirin,could significantly increase rates of sustained virological response in treatment-naive patients with genotype 1 CHC, compared with the current standard of care （pegylated interferon alpha and ribavirin） and had a better efficacy in previous treatment （with pegylated interferon alpha plus ribavirin） - failure patients. The triple therapy scheme could achieve a better efficacy and safety when compared with the current standard of care. BOC and TVR have enabled the treatment of genotype 1 CHC to enter a new era.
出处
《药学服务与研究》
CAS
CSCD
2014年第4期308-311,共4页
Pharmaceutical Care and Research
